![Edward C. Wood](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Edward C. Wood
Algemeen Directeur bij Summit Roundtable
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
John D. Watson | M | - |
ArcScan, Inc.
![]() ArcScan, Inc. Medical SpecialtiesHealth Technology ArcScan, Inc. develops and markets ultrasound scanners for ophthalmology. It provides the software tools to clean up scanned existing paper, maps or photos, and selectively vectorize all or parts of the raster. The company was founded by John D. Watson in February 2007 and is headquartered in Golden, CO. | 17 jaar |
Larry Gold | M | 82 |
The University of Colorado
| 54 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jack J. Kogut | M | 77 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 15 jaar |
Linda K. Neuman | F | 65 |
The University of Colorado
| 7 jaar |
Zuhair Hamed Fayez | M | 79 |
The University of Colorado
| 5 jaar |
Steven A. Gould | M | 77 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 16 jaar |
John J. Hinds | M | - |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
George A. Hides | M | 57 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 14 jaar |
Lee Graber | M | 76 |
The University of Colorado
| 5 jaar |
William L. Chapman | M | - |
The University of Colorado
| 3 jaar |
Douglas A. Miller | M | 73 |
The University of Colorado
| 4 jaar |
H. Paul Cohen | M | - |
The University of Colorado
| 3 jaar |
David Brody | M | 75 |
The University of Colorado
| 4 jaar |
Michael O. Kokesh | M | - |
The University of Colorado
| 4 jaar |
Steven J. Hatchell | M | - |
The University of Colorado
| 4 jaar |
George Hoag | M | 69 |
The University of Colorado
| 4 jaar |
Robert M. Bearman | M | - |
The University of Colorado
| 3 jaar |
Donna M. O'Neill | F | 63 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 5 jaar |
G. Humphries | M | - |
The University of Colorado
| 4 jaar |
Alfred Drumm | M | - |
The University of Colorado
| 2 jaar |
William Barker | M | 75 |
The University of Colorado
| 4 jaar |
Siegfried Weiler | M | 80 |
OXBOW Equities Corp.
| - |
Kip Sutherland Travis | M | - |
The University of Colorado
| 4 jaar |
John C. Knudsen | M | - |
The University of Colorado
| 4 jaar |
Stanley Politan | M | 74 |
The University of Colorado
| 4 jaar |
Douglas Pasquale | M | 69 |
The University of Colorado
| 4 jaar |
Roger Davidson | M | 77 |
The University of Colorado
| 3 jaar |
Jo Anne Miller | F | - |
The University of Colorado
| 4 jaar |
James Ball | M | 73 |
The University of Colorado
| 4 jaar |
Robert W. Rubin | M | - |
The University of Colorado
| 2 jaar |
John F. Reitnouer | M | - |
The University of Colorado
| 4 jaar |
Richard Grigsby | M | - |
The University of Colorado
| 4 jaar |
Mike B. van Sicklen | M | - |
The University of Colorado
| 4 jaar |
Andy Hodgkin | M | - |
The University of Colorado
| 2 jaar |
William B. Mathews | M | 71 |
The University of Colorado
| 4 jaar |
James M. Poage | M | 71 |
The University of Colorado
| 4 jaar |
Dewey P. Bushaw | M | - |
The University of Colorado
| 4 jaar |
Khaldoun Rashid Al Tabari | M | 74 |
The University of Colorado
| 4 jaar |
Robert F. Hill | M | - |
The University of Colorado
| 3 jaar |
Stephen A. Dennis | M | 78 |
The University of Colorado
| 2 jaar |
Wahjudi Prakarsa | M | 86 |
The University of Colorado
| 4 jaar |
John M. Volkman | M | - |
The University of Colorado
| 1 jaar |
Robert Charles Walish | M | 70 |
The University of Colorado
| 4 jaar |
Richard Marc Gordon | M | - |
The University of Colorado
| 2 jaar |
David V. Hampton | M | - |
The University of Colorado
| 4 jaar |
Isabella McCarthy | F | - |
The University of Colorado
| 4 jaar |
Michael S. Newman | M | - |
The University of Colorado
| 4 jaar |
Mohammed Hamad Al-Mady | M | - |
The University of Colorado
| 4 jaar |
Ronald E. Montoya | M | 82 |
The University of Colorado
| 4 jaar |
Craig S. Weber | M | 79 |
The University of Colorado
| 1 jaar |
Jerrie F. Eckelberger | M | 79 |
The University of Colorado
| 3 jaar |
Aleron H. Larson | M | 78 |
The University of Colorado
| 3 jaar |
David A. Savner | M | 79 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 11 jaar |
Bruce S. Chelberg | M | 88 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 20 jaar |
Robert William Dunlap | M | - |
The University of Colorado
| 4 jaar |
Laurel A. Omert | M | 67 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 4 jaar |
John Leone | M | 77 |
The University of Colorado
| 2 jaar |
Eva Essig | F | - |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
Marc D. Doubleday | M | 65 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 21 jaar |
Jay Kleiman | M | - |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | - |
Pamela Saxton | F | 71 |
The University of Colorado
| 4 jaar |
Sophia H. Twaddell | F | 72 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 6 jaar |
Paul M. Ness | M | 78 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 7 jaar |
Robert Bland | M | 71 |
The University of Colorado
| 4 jaar |
Alan L. Heller | M | 70 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 3 jaar |
Robert McGinnis | M | 60 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 12 jaar |
Larry R. Hootnick | M | - |
OXBOW Equities Corp.
| - |
Charles H. House | M | 83 |
The University of Colorado
| 1 jaar |
Jill B. W. Sisson | F | 76 |
The University of Colorado
| 3 jaar |
Steve Signer | M | - |
The University of Colorado
| 4 jaar |
Dennis Hatchell | M | 74 |
The University of Colorado
| 4 jaar |
Michael C. Dermody | M | - |
The University of Colorado
| 4 jaar |
Christine A. Petersen | M | - |
The University of Colorado
| 2 jaar |
Dave Klenzendorf | M | - |
The University of Colorado
| 6 jaar |
Karen Mathis | M | - |
The University of Colorado
| 3 jaar |
Casey Ryan | M | - |
The University of Colorado
| 3 jaar |
James Gallogly | M | 71 |
The University of Colorado
| 4 jaar |
Thomas Michael Jeffers | M | - |
The University of Colorado
| 4 jaar |
Cathy Hetrick | F | 75 |
The University of Colorado
| 4 jaar |
Daniel Scott Perkins | M | - |
The University of Colorado
| 4 jaar |
Simon Clarke | M | - |
ArcScan, Inc.
![]() ArcScan, Inc. Medical SpecialtiesHealth Technology ArcScan, Inc. develops and markets ultrasound scanners for ophthalmology. It provides the software tools to clean up scanned existing paper, maps or photos, and selectively vectorize all or parts of the raster. The company was founded by John D. Watson in February 2007 and is headquartered in Golden, CO. | 4 jaar |
William J. Pincus | M | 70 |
The University of Colorado
| 4 jaar |
Robert Hess | M | - |
The University of Colorado
| 1 jaar |
Dennis Bernard Fitzpatrick | M | 80 |
The University of Colorado
| 3 jaar |
David F. Phillips | M | - |
OXBOW Equities Corp.
| - |
André Denis | M | - |
OXBOW Equities Corp.
| - |
John F. Bierbaum | M | 80 |
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | 7 jaar |
David Hirsh | M | 85 |
The University of Colorado
| 14 jaar |
Sobhi Batterjee | M | - |
The University of Colorado
| 1 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 85 | 95.51% |
Canada | 4 | 4.49% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Edward C. Wood
- Persoonlijk netwerk